Uploaded March 2026 | Updated September 2026, 10 hours ago
Join Dr. William Dahut, the Chief Scientific Officer of the American Cancer Society, and Steve Curtis, the Interim Managing Director of BrightEdge, the venture capital arm of the American Cancer Society, as they walk us through the research ecosystem including: governmental vs. non-governmental driven-research and funding; the process of translating research into treatments for patients; and the relationship between public policy and the impact in fighting cancer from prevention through survivorship.
Kelly Moran is a leader at the American Cancer Society who helps convene donors, advocates, researchers, and community partners around the mission to end cancer as we know it, for everyone. In this discussion, she frames how ACS supports research, advocacy, and patient care across every cancer type.
Dr. Bill Dahut is the Chief Scientific Officer of the American Cancer Society. Before joining ACS, he served in senior leadership roles at the National Cancer Institute, including Scientific Director for Clinical Research, head of the Prostate Cancer Clinical Research Section, and NCI Clinical Director. He is a medical oncologist with deep expertise in cancer research, prevention, and screening.
Dr. Steve Curtis is the Interim Managing Director of Bright Edge and Vice President of Innovation and Impact Investing at the American Cancer Society. He previously led oncology-focused investment efforts and has experience across biotech, venture philanthropy, and cancer genetics. His work focuses on turning promising discoveries into companies, diagnostics, and treatments that can reach patients.
If this conversation gave you a new perspective on how cancer breakthroughs happen, subscribe and share it with someone who cares about science, medicine, biotech, or patient advocacy. This is the kind of behind-the-scenes discussion that shows why progress against cancer takes all of us.
Chapters
0:00 Introduction
1:18 Meet the speakers
3:02 What the American Cancer Society actually does
6:05 Why this is a breakthrough era for cancer research
10:12 The funding surge and why partnerships matter
13:45 Cancer survival progress and major trends
17:40 The rise of colorectal cancer in younger adults
22:10 Prostate cancer screening and precision screening
26:05 Ovarian cancer prevention and fallopian tube research
29:40 Rural cancer disparities and long-term cohort studies
33:20 How AI is changing cancer detection and treatment
38:05 Colonoscopy quality, AI, and early detection
42:15 How Bright Edge turns research into treatments
47:18 The biotech funding crunch and why it matters
53:05 How ACS supports entrepreneurs and startups
57:12 Access, affordability, and getting treatments to patients
1:00:25 Q&A on funding uncertainty, AI, and future innovation
#CancerResearch #CancerTreatment #MedicalBreakthroughs #Biotech #HealthcareInnovation
Join Dr. William Dahut, the Chief Scientific Officer of the American Cancer Society, and Steve Curtis, the Interim Managing Director of BrightEdge, the venture capital arm of the American Cancer Society, as they walk us through the research ecosystem including: governmental vs. non-governmental driven-research and funding; the process of translating research into treatments for patients; and the relationship between public policy and the impact in fighting cancer from prevention through survivorship.
Kelly Moran is a leader at the American Cancer Society who helps convene donors, advocates, researchers, and community partners around the mission to end cancer as we know it, for everyone. In this discussion, she frames how ACS supports research, advocacy, and patient care across every cancer type.
Dr. Bill Dahut is the Chief Scientific Officer of the American Cancer Society. Before joining ACS, he served in senior leadership roles at the National Cancer Institute, including Scientific Director for Clinical Research, head of the Prostate Cancer Clinical Research Section, and NCI Clinical Director. He is a medical oncologist with deep expertise in cancer research, prevention, and screening.
Dr. Steve Curtis is the Interim Managing Director of Bright Edge and Vice President of Innovation and Impact Investing at the American Cancer Society. He previously led oncology-focused investment efforts and has experience across biotech, venture philanthropy, and cancer genetics. His work focuses on turning promising discoveries into companies, diagnostics, and treatments that can reach patients.
If this conversation gave you a new perspective on how cancer breakthroughs happen, subscribe and share it with someone who cares about science, medicine, biotech, or patient advocacy. This is the kind of behind-the-scenes discussion that shows why progress against cancer takes all of us.
Chapters
0:00 Introduction
1:18 Meet the speakers
3:02 What the American Cancer Society actually does
6:05 Why this is a breakthrough era for cancer research
10:12 The funding surge and why partnerships matter
13:45 Cancer survival progress and major trends
17:40 The rise of colorectal cancer in younger adults
22:10 Prostate cancer screening and precision screening
26:05 Ovarian cancer prevention and fallopian tube research
29:40 Rural cancer disparities and long-term cohort studies
33:20 How AI is changing cancer detection and treatment
38:05 Colonoscopy quality, AI, and early detection
42:15 How Bright Edge turns research into treatments
47:18 The biotech funding crunch and why it matters
53:05 How ACS supports entrepreneurs and startups
57:12 Access, affordability, and getting treatments to patients
1:00:25 Q&A on funding uncertainty, AI, and future innovation
#CancerResearch #CancerTreatment #MedicalBreakthroughs #Biotech #HealthcareInnovation
